ANTX stock icon

AN2 Therapeutics
ANTX

$1.99
3.49%
 

About: AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Employees: 36

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 15

6% more funds holding

Funds holding: 52 [Q4 2023] → 55 (+3) [Q1 2024]

6.41% less ownership

Funds ownership: 69.4% [Q4 2023] → 62.99% (-6.41%) [Q1 2024]

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

86% less capital invested

Capital invested by funds: $423M [Q4 2023] → $60.9M (-$362M) [Q1 2024]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$2
1%
upside
Avg. target
$11.25
465%
upside
High target
$30
1,408%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
Evercore ISI Group
Liisa Bayko
1%upside
$2
In-Line
Maintained
16 May 2024
JMP Securities
Roy Buchanan
202%upside
$6
Market Outperform
Upgraded
2 Apr 2024
Leerink Partners
Joseph Schwartz
252%upside
$7
Market Perform
Downgraded
13 Feb 2024
JMP Securities
Roy Buchanan
1,408%upside
$30
Market Outperform
Initiated
4 Jan 2024

Financial journalist opinion